Idraparinux - Investigational Agent for the Treatment and Prevention of Thromboembolic Events
Key Data:
Drug (brand/generic)
Idraparinux
Company/licensee
Sanofi-Aventis
Therapy class
Anticoagulant
Product description
Selective inhibitor of coagulation Factor Xa
Current indication
VTE prophylaxis and prevention of stroke in patients with atrial fibrillation
Market sector
Cardiovascular
Development status
Phase III
